$7.6 M

IMUN Mkt cap, 17-Sept-2020
Immune Therapeutics Net income (Q2, 2020)-803.5 K
Immune Therapeutics EBIT (Q2, 2020)-18 K
Immune Therapeutics Cash, 30-Jun-202045.3 K
Immune Therapeutics EV13.1 M

Immune Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

16.2k3.5k113.5k

Revenue growth, %

(79%)

Cost of goods sold

47.7k

Gross profit

65.8k

Gross profit Margin, %

58%

R&D expense

22.0m2.4m977.2k444.2k399.4k144.1k336.1k

General and administrative expense

71.1m4.1m2.7m3.9m2.8m3.2m2.4m

Operating expense total

93.1m16.4m3.7m4.3m3.2m4.2m2.7m

Depreciation and amortization

2.9m2.9m594.8k1.6k826.01.7k2.1k

EBIT

(96.0m)(45.3m)(15.8m)(14.3m)(5.9m)(4.1m)(2.8m)

EBIT margin, %

(97567%)(412125%)(3599%)

Interest expense

10.1m4.7m1.1m5.5m2.0m4.5m

Investment income

(376.2k)

Net Income

(106.1m)(49.9m)(16.9m)(19.8m)(7.9m)(8.6m)(3.4m)

Immune Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

406.6k192.0k23.1k74.4k14.7k5.9k4.9k

Accounts Receivable

16.2k

Prepaid Expenses

215.9k30.0k

Inventories

178.1k82.8k

Current Assets

622.5k222.0k39.3k74.4k192.8k88.7k4.9k

PP&E

5.6k4.2k1.7k2.5k2.8k691.0

Total Assets

19.2m6.1m41.2k76.4k195.5k91.6k5.8k

Accounts Payable

839.9k2.1m1.9m1.8m2.3m2.1m2.7m

Short-term debt

4.4m7.3m4.6m4.8m5.2m5.5m

Current Liabilities

2.4m3.4m6.0m9.2m11.3m11.3m13.7m

Long-term debt

327.5k

Non-Current Liabilities

121.1k327.5k

Total Debt

1.6m7.6m4.6m4.8m5.2m5.5m

Total Liabilities

2.6m3.7m6.0m9.2m11.3m11.3m13.7m

Common Stock

74.2k13.4k17.5k38.7k43.4k46.0

Additional Paid-in Capital

308.1m338.0m343.4m360.4m366.6m369.9m370.9m

Retained Earnings

(283.0m)(333.5m)(349.9m)(365.7m)(373.0m)(381.2m)(384.6m)

Total Equity

16.6m2.4m(6.0m)(9.1m)(11.1m)(11.3m)(13.7m)

Debt to Equity Ratio

0.1 x3.2 x-0.8 x-0.4 x-0.5 x

Debt to Assets Ratio

0.1 x1.3 x111.3 x24.6 x56.6 x

Financial Leverage

1.2 x2.6 x0 x0 x0 x0 x0 x

Quarterly

USDQ1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

176.2k231.5k207.7k233.7k58.7k58.6k30.9k22.4k153.9k132.8k64.3k22.2k98.1k45.0k22.6k30.4k5.9k5.7k21.4k6.5k6.2k45.3k

Accounts Receivable

2.1k7.7k12.7k19.7k2.7k

Prepaid Expenses

130.0k30.9k45.0k42.5k35.0k49.7k30.0k30.0k45.4k1.6k11.3k

Inventories

214.3k158.6k158.6k158.6k82.8k

Current Assets

306.2k262.4k252.7k276.2k93.7k108.3k62.9k60.1k211.9k153.4k78.2k22.2k98.1k45.0k236.9k189.0k158.6k164.5k88.5k21.4k6.5k6.2k45.3k

PP&E

2.0k3.5k4.6k5.0k5.6k4.9k3.6k2.9k2.3k1.1k701.0402.01.7k3.1k2.8k4.1k3.6k3.2k2.4k2.1k1.8k531.0373.0

Total Assets

21.0m20.3m19.5m18.1m17.3m16.6m5.7m5.6m5.6m154.8k79.1k22.8k100.0k48.3k239.9k193.3k163.7k167.9k91.1k23.7k8.4k6.9k45.8k

Accounts Payable

362.4k438.2k629.8k1.0m1.6m1.8m1.9m1.9m1.9m1.9m1.5m1.5m1.7m1.8m2.2m2.4m1.7m1.5m2.0m2.1m2.3m2.8m2.8m

Short-term debt

3.7m5.1m5.9m6.6m2.0m2.5m3.4m2.8m3.5m3.6m4.7m4.3m4.4m5.2m4.4m4.8m5.5m5.6m5.6m5.5m5.6m

Current Liabilities

1.8m2.2m2.4m3.2m4.0m2.7m3.7m3.9m4.6m6.3m7.0m7.5m10.4m7.9m8.6m11.4m9.8m10.9m11.8m12.6m13.5m14.5m15.3m

Non-Current Liabilities

189.5k139.5k121.1k101.1k71.1k354.4k429.0k109.3k

Total Debt

1.7m2.8m5.9m6.6m2.0m2.5m3.4m2.8m3.5m3.6m4.7m4.3m4.4m5.2m4.4m4.8m5.5m5.6m5.6m5.5m5.6m

Total Liabilities

2.0m2.3m2.5m3.3m4.0m2.7m4.0m4.4m4.7m6.3m7.0m7.5m10.4m7.9m8.6m11.4m9.8m10.9m11.8m12.6m13.5m14.5m15.3m

Common Stock

53.5k57.6k62.6k86.4k90.9k129.0k14.5k14.9k17.5k20.5k21.4k23.6k27.6k33.3k35.7k39.0k39.9k41.6k45.6k45.6k46.046.046.0

Additional Paid-in Capital

247.6m266.2m272.7m322.6m324.4m338.4m339.8m340.2m343.9m351.3m354.3m357.4m361.5m364.8m365.3m367.2m367.8m369.4m370.1m370.1m370.2m370.9m370.9m

Retained Earnings

(191.6m)(216.3m)(236.3m)(300.7m)(307.3m)(318.5m)(336.6m)(338.8m)(342.6m)(354.4m)(358.3m)(362.3m)(368.3m)(368.0m)(369.4m)(373.6m)(377.7m)(380.3m)(389.9m)(382.7m)(383.7m)(385.4m)(386.2m)

Total Equity

19.0m17.9m17.0m14.8m13.3m13.9m1.7m1.2m935.3k(6.2m)(6.9m)(7.5m)(10.3m)(7.9m)(8.4m)(11.2m)(9.6m)(10.7m)(11.8m)(12.5m)(13.5m)(14.5m)(15.3m)

Debt to Equity Ratio

0.1 x0.2 x0.4 x0.5 x1.2 x2.1 x3.6 x-0.5 x-0.5 x-0.5 x-0.5 x-0.5 x-0.5 x-0.5 x-0.5 x-0.4 x-0.5 x-0.4 x-0.4 x

Debt to Assets Ratio

0.1 x0.2 x0.3 x0.4 x0.3 x0.5 x0.6 x18.3 x43.7 x157.1 x47.4 x89.3 x18.2 x26.7 x26.9 x28.6 x60.2 x235.8 x805.3 x

Financial Leverage

1.1 x1.1 x1.1 x1.2 x1.3 x1.2 x3.4 x4.6 x6 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x

Immune Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(106.1m)(49.9m)(16.9m)(19.8m)(7.9m)(8.6m)(3.4m)

Depreciation and Amortization

2.9m2.9m594.8k1.6k826.01.7k2.1k

Accounts Receivable

(16.2k)13.5k

Inventories

(178.1k)95.3k82.8k

Accounts Payable

553.2k1.8m900.5k541.0k919.1k341.6k895.0k

Cash From Operating Activities

(6.6m)(3.8m)(2.8m)(2.8m)(2.1m)(1.4m)(934.0)

Purchases of PP&E

(5.8k)(1.1k)(1.7k)(1.5k)(2.0k)

Cash From Investing Activities

(166.4k)(58.5k)(1.7k)(1.5k)(2.0k)

Short-term Borrowings

(100.0k)(75.9k)(319.9k)

Cash From Financing Activities

6.8m3.7m2.7m2.9m2.0m1.4m

Net Change in Cash

93.5k(214.6k)(168.8k)51.2k(59.7k)(8.9k)(934.0)

Interest Paid

4.5k20.5k29.6k43.0k59.6k16.0k

Quarterly

Immune Therapeutics Ratios

USDQ1, 2013

Financial Leverage

1.1 x